A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Guselkumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms Discover-1
- Sponsors Janssen Research & Development
- 08 Aug 2017 Planned initiation date changed from 11 Aug 2017 to 21 Aug 2017.
- 11 Jul 2017 Planned initiation date changed from 2 Aug 2017 to 11 Aug 2017.
- 15 Jun 2017 Planned End Date changed from 19 Jun 2020 to 20 Jul 2020.